prikaz prve stranice dokumenta Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).
  Preuzmi
PDF 2.78 MB
Znanstveni rad - Izvorni znanstveni rad
Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).
Translational Lung Cancer Research, 8 (2019), 6; 1000-1015. https://doi.org/10.21037/tlcr.2019.12.08
Šutić, Maja; Motzek, Antje; Bubanović, Gordana; Linke, Matthias; Sabol, Ivan; Vugrek, Oliver; Ozretić, Petar; Brčić, Luka; Seiwerth, Sven; Debeljak, Željko; Jakovčević, Antonija; Janevski, Zoran; Stančić-Rokotov, Dinko; Vukić-Dugac, Andrea; Jakopović, Marko; Samaržija, Miroslav; Zechner, Ulrich; Knežević, Jelena Više autora...

Citirajte ovaj rad

Šutić, M., Motzek, A., Bubanović, G., Linke, M., Sabol, I., Vugrek, O. ... Knežević, J. (2019). Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).. Translational Lung Cancer Research, 8. (6), 1000-1015. doi: 10.21037/tlcr.2019.12.08

Šutić, Maja, et al. "Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).." Translational Lung Cancer Research, vol. 8, br. 6, 2019, str. 1000-1015. https://doi.org/10.21037/tlcr.2019.12.08

Šutić, Maja, Antje Motzek, Gordana Bubanović, Matthias Linke, Ivan Sabol, Oliver Vugrek, Petar Ozretić, et al. "Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).." Translational Lung Cancer Research 8, br. 6 (2019): 1000-1015. https://doi.org/10.21037/tlcr.2019.12.08

Šutić, M., et al. (2019) 'Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).', Translational Lung Cancer Research, 8(6), str. 1000-1015. doi: 10.21037/tlcr.2019.12.08

Šutić M, Motzek A, Bubanović G, Linke M, Sabol I, Vugrek O, i sur.. Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).. Translational Lung Cancer Research [Internet]. 2019. [pristupljeno 18.04.2024.];8(6):1000-1015. doi: 10.21037/tlcr.2019.12.08

M. Šutić, et al., "Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).", Translational Lung Cancer Research, vol. 8, br. 6, str. 1000-1015, 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:239:910974. [Citirano: 18.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:239:910974
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).
AutorMaja Šutić
MBZ: 362344
AutorAntje Motzek
AutorGordana Bubanović
MBZ: 319765
AutorMatthias Linke
AutorIvan Sabol
MBZ: 268915
AutorOliver Vugrek
MBZ: 232935
AutorPetar Ozretić
MBZ: 295840
AutorLuka Brčić
MBZ: 272221
AutorSven Seiwerth
MBZ: 149676
AutorŽeljko Debeljak
MBZ: 296571
AutorAntonija Jakovčević
AutorZoran Janevski
AutorDinko Stančić-Rokotov
MBZ: 216873
AutorAndrea Vukić-Dugac
MBZ: 353752
AutorMarko Jakopović
MBZ: 278365
AutorMiroslav Samaržija
MBZ: 146943
AutorUlrich Zechner
AutorJelena Knežević
MBZ: 242431
Autorova ustanovaInstitut Ruđer Bošković
Autorova ustanova(Klinički bolnički centar Osijek)
Autorova ustanovaSveučilište Josipa Jurja Strossmayera u Osijeku
Medicinski fakultet Osijek
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Onkologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Imunologija
Sažetak (engleski)
BACKGROUND: Lung cancer is the leading cause of cancer-related death worldwide, with 5-year overall survival less than 15%. Therefore, it is essential to find biomarkers for early detection and prognosis. Aberrant DNA methylation is a common feature of human cancers and its utility is already recognized in cancer management. The aim of this study was to explore the diagnostic and prognostic value of the promoter methylation status of the ASC/TMS1/PYCARD and MyD88 genes, key adaptor molecules in the activation of the innate immune response and apoptosis pathways. METHODS: A total of 50 non-small cell lung cancer (NSCLC) patients were enrolled in the study. Methylation of bisulphite converted DNA was quantified by pyrosequencing in fresh frozen malignant tissues and adjacent non-malignant tissues. Associations between methylation and lung function, tumor grade and overall survival were evaluated using receiver-operating characteristics (ROC) analysis and statistical tests of hypothesis. RESULTS: Methylation level of tested genes is generally low but significantly decreased in tumor tissues (ASC/TMS1/PYCARD, P<0.0001; MyD88, P<0.0002), which correlates with increased protein expression. Three CpG sites were identified as promising diagnostic marker candidates; CpG11 (-63 position) in ASC/TMS1/PYCARD and CpG1 (-253 position) and 2 (-265 position) in MyD88. The association study showed that the methylation status of the ASC/TMS1 CpG4 site (-34 position) in malignant and non-malignant tissues is associated with the overall survival (P=0.019) and the methylation status of CpG8 site (-92 position) is associated with TNM-stage (P=0.011). CONCLUSIONS: The methylation status of the ASC/TMS1/PYCARD and MyD88 promoters are promising prognostic biomarker candidates. However, presented results should be considered as a preliminary and should be confirmed on the larger number of the samples.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaTranslational Lung Cancer Research
Brojčani podacivol. 8, br. 6, str. 1000-1015
p-ISSN2218-6751
e-ISSN2226-4477
DOIhttps://doi.org/10.21037/tlcr.2019.12.08
URN:NBNurn:nbn:hr:239:910974
Datum objave publikacije2019
URL dokumentahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976376/
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2020-04-29 09:39:20